1887

Abstract

Oka varicella vaccine induces humoral and cell-mediated immunity to varicella-zoster virus (VZV), even in immunocompromised hosts. This vaccine showed novel adjuvant activity against co-inoculated hepatitis B surface antigen (HBsAg). Either a mixed inoculation of HBsAg with heat-inactivated Oka varicella vaccine at one site or a separate inoculation of HBsAg and live vaccine at different sites induced an antibody response but failed to induce delayed type hypersensitivity (DTH) to HBsAg. In contrast, immunization of HBsAg mixed with live vaccine induced DTH and an enhanced antibody response to HBsAg. The adjuvant activity of Oka varicella vaccine was similar in terms of antibody production to that of alum adjuvant. A T helper cell-dominant immunity to VZV and HBsAg continued for 1 year. Oka varicella vaccine combined with a foreign antigen may serve as a novel polyvalent vaccine for the infectious diseases for which cell-mediated immunity is beneficial.

Loading

Article metrics loading...

/content/journal/jgv/10.1099/vir.0.18692-0
2003-02-01
2021-03-08
Loading full text...

Full text loading...

/deliver/fulltext/jgv/84/2/vir840287.html?itemId=/content/journal/jgv/10.1099/vir.0.18692-0&mimeType=html&fmt=ahah

References

  1. Abbas A. K., Murphy K. M., Sher A.. 1996; Functional diversity of helper T lymphocytes. Nature383:787–793
    [Google Scholar]
  2. Arvin A. M., Gershon A. A.. 1996; Live attenuated varicella vaccine. Annu Rev Microbiol50:59–100
    [Google Scholar]
  3. Asano Y., Shiraki K., Takahashi M., Nagai H., Ozaki T., Yazaki T.. 1981; Soluble skin test antigen of varicella-zoster virus prepared from the fluid of infected cultures. J Infect Dis143:684–692
    [Google Scholar]
  4. Asano Y., Itakura N., Hiroishi Y.. 7 other authors 1985; Viral replication and immunologic responses in children naturally infected with varicella-zoster virus and in varicella vaccine recipients. J Infect Dis152:863–868
    [Google Scholar]
  5. Baba K., Tsuda N., Yabuuchi H., Konishi S., Fujinami A., Tsujino G., Takahashi M.. 1980; Prevention of varicella in urgent cases by passive transfer of vaccine-induced immunity. Biken J23:89–94
    [Google Scholar]
  6. Berger R., Luescher D., Just M.. 1984; Enhancement of varicella-zoster-specific immune responses in the elderly by boosting with varicella vaccine. J Infect Dis149:647–649
    [Google Scholar]
  7. Berger R., Trannoy E., Hollander G., Bailleux F., Rudin C., Creusvaux H.. 1998; A dose-response study of a live attenuated varicella-zoster virus (Oka strain) vaccine administered to adults 55 years of age and older. J Infect Dis178 (Suppl. 1):S99–S103
    [Google Scholar]
  8. Diaz P. S., Smith S., Hunter E., Arvin A. M.. 1989; T lymphocyte cytotoxicity with natural varicella-zoster virus infection and after immunization with live attenuated varicella vaccine. J Infect Dis142:636–641
    [Google Scholar]
  9. Finkelman F. D.. 1995; Relationships among antigen presentation, cytokines, immune deviation, and autoimmune disease. J Exp Med182:279–282
    [Google Scholar]
  10. Heineman T. C., Connelly B. L., Bourne N., Stanberry L. R., Cohen J.. 1995; Immunization with recombinant varicella-zoster virus expressing herpes simplex virus type 2 glycoprotein D reduces the severity of genital herpes in guinea pigs. J Virol69:8109–8113
    [Google Scholar]
  11. Jack A. D., Hall A. J., Maine N., Mendy M., Whittle H. C.. 1999; What level of hepatitis B antibody is protective?. J Infect Dis179:489–492
    [Google Scholar]
  12. Jenkins D. E., Redman R. L., Lam E. M., Liu C., Lin I., Arvin A. M.. 1998; Interleukin (IL)-10, IL-12, and interferon-γ production in primary and memory immune responses to varicella-zoster virus. J Infect Dis178:940–948
    [Google Scholar]
  13. Kamiya H., Ihara T., Hattori A., Iwasa T., Sakurai M., Izawa T., Yamada A., Takahashi M.. 1977; Diagnostic skin reactions with varicella virus antigen and clinical application of the test. J Infect Dis136:784–788
    [Google Scholar]
  14. Kamiyama T., Sato H., Takahara T., Kageyama S., Shiraki K.. 2000; Novel immunogenicity of Oka varicella vaccine vector expressing hepatitis B surface antigen. J Infect Dis181:1158–1161
    [Google Scholar]
  15. LaRussa P., Steinberg S. P., Seeman M. D., Gershon A. A.. 1985; Determination of immunity to varicella-zoster virus by means of an intradermal skin test. J Infect Dis152:869–875
    [Google Scholar]
  16. Lau D. T., Khokhar M. F., Doo E.. 10 other authors 2000; Long-term therapy of chronic hepatitis B with lamivudine. Hepatology32:828–834
    [Google Scholar]
  17. Levin M. J., Murray M., Zerbe G. O., White C. J., Hayward A. R.. 1994; Immune response of elderly persons 4 years after receiving a live attenuated varicella vaccine. J Infect Dis170:522–526
    [Google Scholar]
  18. Levin M. J., Barber D., Goldblatt E., Jones M., LaFleur B., Chan C., Stinson D., Zerbe G. O., Hayward A. R.. 1998; Use of a live attenuated varicella vaccine to boost varicella-specific immune responses in seropositive people 55 years of age and older: duration of booster effect. J Infect Dis178 (Suppl. 1):S109–S112
    [Google Scholar]
  19. Moser M., Murphy K. M.. 2000; Dendritic cell regulation of Th1–Th2 development. Nat Immunol1:199–205
    [Google Scholar]
  20. Rossol S., Marinos G., Carucci P., Singer M. V., Williams R., Naoumov N. V.. 1997; Interleukin-12 induction of Th1 cytokines is important for viral clearance in chronic hepatitis B. J Clin Invest99:3025–3033
    [Google Scholar]
  21. Sato H., Kageyama S., Imakita M., Ida M., Yamamura J., Kurokawa M., Shiraki K.. 1998; Immune response to varicella-zoster virus glycoproteins in guinea pigs infected with Oka varicella vaccine. Vaccine16:1263–1269
    [Google Scholar]
  22. Shiraki K., Yamanishi K., Takahashi M.. 1984; Biologic and immunologic characterization of the soluble skin-test antigen of varicella-zoster virus. J Infect Dis149:501–504
    [Google Scholar]
  23. Shiraki K., Hayakawa Y., Mori H., Namazue J., Takamizawa A., Yoshida I., Yamanishi K., Takahashi M.. 1991; Development of immunogenic recombinant Oka varicella vaccine expressing hepatitis B virus surface antigen. J Gen Virol72:1393–1399
    [Google Scholar]
  24. Shiraki K., Sato H., Yamamura J., Li Z. H., Yokoyama T., Hasegawa T., Okuno T., Kurokawa M., Kageyama S.. 1997; Functions of purified gB, gE : gI, and gH : gL, and their sialyl residues in varicella-zoster virus infection. Arch Virol142:2295–2301
    [Google Scholar]
  25. Shiraki K., Sato H., Yoshida Y., Yamamura J., Tsurita M., Kurokawa M., Kageyama S.. 2001; Construction of Oka varicella vaccine expressing human immunodeficiency virus Env antigen. J Med Virol64:89–95
    [Google Scholar]
  26. Singh M., O'Hagan D.. 1999; Advance in vaccine adjuvants. Nat Biotechnol17:1075–1081
    [Google Scholar]
  27. Takahashi M., Otsuka T., Okuno Y., Asano Y., Yazaki T.. 1974; Live vaccine used to prevent the spread of varicella in children in hospital. Lancetii:1288–1290
    [Google Scholar]
  28. Takahashi M., Iketani T., Sasada K., Hara J., Kamiya H., Asano Y., Baba K., Shiraki K.. 1998; Immunization of the elderly and patients with collagen vascular diseases with live varicella vaccine and use of varicella skin antigen. J Infect Dis166 (Suppl. 1):S58–S62
    [Google Scholar]
  29. Takahashi M., Kamiya H., Asano Y., Shiraki K., Baba K., Otsuka T., Hirota T., Yamanishi K.. 2001; Immunization of the elderly to boost immunity against varicella-zoster virus (VZV) as assessed by VZV skin test reaction. Arch Virol17:161–172
    [Google Scholar]
  30. Vazquez M., LaRussa P. S., Gershon A. A., Steinberg S. P., Freudigman K., Shapiro E. D.. 2001; The effectiveness of the varicella vaccine in clinical practice. New Engl J Med344:955–960
    [Google Scholar]
http://instance.metastore.ingenta.com/content/journal/jgv/10.1099/vir.0.18692-0
Loading
/content/journal/jgv/10.1099/vir.0.18692-0
Loading

Data & Media loading...

Most cited this month Most Cited RSS feed

This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error